Found 3083 related files. Current in page 13
Increasing Number of Private Hospitals Driving the Assembly Lines for Medical Devices Market - New Report by MicroMarket Monitor
Alcoholic Beverages Market Report segment the market by types of alcoholic beverages, its packaging types, application, and geography.
Intellectual property – the process which includes the creation, manufacture and marketing of a product – can be a manufacturer’s most valuable asset. Intellectual property rights (IPR) violations can come in a variety of forms including counterfeiting, trademark infringement, gray market, diversion, country of origin or non-compliant parts. It is a serious issue and, in today’s global marketplace, a company may never know its rights are being violated. Counterfeit products are at the forefront of these IPR issues. Any recognizable brand is at risk of being counterfeited – from clothing and handbags, music and movies, pharmaceuticals and parts for automobiles and heavy duty trucks and equipment. The global counterfeit problem is estimated at $600 billion per year, according to the Federal Trade Commission (FTC) and the World Customs Organization in Interpol. As a result, the FBI has labeled counterfeiting as the “Crime of the 21st Century”. Counterfeiting is not a victimless crime. Consider that: • Counterfeiting steals desirable manufacturing jobs. • Counterfeiting destroys brand reputation of legitimate companies and poses product liability claims. • The sale of counterfeit goods has been linked to organized crime and terrorist organizations. The motor vehicle parts industry – those manufacturers who produce the parts and components used to repair everything from passenger cars to over-the-road trucks – have been hit hard by counterfeiting. It is estimated that counterfeiting costs the global motor vehicle parts industry $12 billion a year and $3 billion in the United States alone, according to the Federal Trade Commission (FTC) and the World Customs Organization in Interpol. The problem grows larger every year – in a report released in June 2006, Frost & Sullivan projected global losses as high as $45 billion by 2011.
Peritonsillar abscess Emily Macassey, Patrick J D Dawes In this issue of the NZMJ, Love et al1 report interesting observations about patterns of epidemiology and microbiology of peritonsillar abscess (PTA) in Canterbury and make comparisons with previous studies performed at Christchurch Hospital. The report contains some valuable observations when it comes to the treatment of the condition. Peritonsillar abscess (also known as quinsy) is a potentially life-threatening infection of the potential space adjacent to the tonsillar capsule in the oropharynx. It can be difficult for doctors unfamiliar with PTA to differentiate it from severe tonsillitis but unilaterality of symptoms and inability to swallow saliva are good indicators. The main differentiating signs seen are trismus, swelling or bulging of the soft palate, medialisation of the tonsil and deviation of the uvula.2 PTA is life-threatening because of both its potential for airway obstruction and spread to the parapharyngeal and retropharyngeal spaces. It is reported that George Washington probably died from quinsy in 1799.3 It is reassuring that 97.3% of isolates are reported as penicillin sensitive. Penicillin remains the first-line antibiotic for all tonsillar infections and this is the sole agent used in many New Zealand hospitals. In other countries resistance rates vary from 10– 50%.4 In a survey of UK consultants, 28% had a preference for penicillin monotherapy, whilst penicillin combined with metronidazole was the choice of 44%.3 Research has shown that even when patients have penicillin resistant organisms, treatment with aspiration and parenteral penicillin still achieves clinical resolution.5 This is in accordance with principles of abscess management where drainage is paramount.
Hemorrhagic tonsillitis is a rare complication of acute or chronic tonsillitis and could be fatal in some cases. Few cases were reported in the literature. Here we present a seven years old female child who was presented with bilateral tonsillar hemorrhage and a history of chronic recurrent tonsillitis. Her investigations and management are discussed. Key words: Hemorrhagic, Streptococcus, Tonsillitis, Bleeding JRMS February 2010, 17(Supp 1): 33-34 The tonsils are lymph tissues located on either side of the back of the throat. Their functions are to destroy microorganisms entering the nose and throat. Most episodes of acute pharyngotonsillitis are viral. Group A beta-hemolytic Streptococcus is the most common cause of bacterial infection in the tonsils. Others causes are beta-hemolytic Streptococcus species (Lancefield Groups, Group C or B),(1,2) Staphylococcus aureus, gram-negative organisms and Mycoplasma pneumonia are other causes.(1) Hemorrhagic tonsillitis, which is a complication of acute or chronic tonsillitis, is almost always found in association with peritonsillar abscess and is rarely reported in the new antibiotic era. It is a serious condition and could be fatal in some cases if hemorrhage was not controlled from tonsillar blood vessels.(3) Here we report the case of a seven years old female child with severe toxicity, follicular tonsillitis, and bleeding tonsils that presented to our emergency pediatric clinic, and was diagnosed as a case of hemorrhagic tonsillitis. A seven years old female child presented to our outpatient’s pediatric clinic with high fever, toxicity, malaise, inability to swallow, and sore throat. Physical examination showed a blood pressure of 90/40mmHg, pulse 100/minute and axillary temperature of 39 degrees Celcius. Throat examination showed follicular tonsillitis with bleeding tonsils (Fig.1). An otorhinolaryngologist (ENT) doctor was consulted and otopharyngeal examination showed hugely enlarged, swollen, congested and bluish tonsils bilaterally with whitish debris on both of them. There were diffuse superficial oozing points on both tonsils and bilateral tender and enlarged cervical lymph nodes. A pack soaked with 2% hydrogen peroxide was applied locally for both sides and silver nitrate cautery was done which controlled the bleeding points. Her throat swab showed alpha-hemolytic Streptococcus, no serological typing for the isolated Streptococcus was done. Complete blood count showed Leucocytosis with neutrophilia. Her prothrombin time (PT) and partial thromboplastin time (PTT) were normal.
A quarterly publication of the Manchester Historical Society, Inc. / 175 Pine Street / Manchester, Connecticut 06040 / (860) 647-9983 The Winds Blew, The Trees Flew: Pitkin Family Wagon at East Granby Rally T he horse-drawn express wagon in our collection was displayed at the East Granby horse-drawn vehicle rally in October. The weather was perfect and a large number of wagons, carriages, sleighs and even a real Concord stage coach were present. Our wagon was originally owned by the William Pitkin family of Pitkin Street in the early 1930s. Society member Mary Jane Pitkin Cooper remem- bers when her father brought it home for the first time. Her brothers and sisters and the neighborhood children really enjoyed riding in it and even putting it to work on the family farm (where Concordia Lutheran Church now stands). The family had a pony named “Billy” who provided the one “horse” power for the wagon. John Hovey’s grandson Andrew Pryce sitting in the driver’s seat of the Pitkin wagon. New Wheelchair Ramp Installed at Entrance to Loom Room Project Completed by Manchester Eagle Scout C hris Kopytko of Manchester Boy Scout Troop 25 recently constructed a wheelchair ramp at the entrance to the Loom Room on the ground floor of the History Center building for his Eagle Scout project. He also rebuilt the stairway leading to the rear door of the Loom Room. Chris, working with several other scouts designed the project and obtained the required materials. The exterior ramp and platform are constructed of pressure treated wood, for longevity. This makes the Loom Room wheelchair accessible for visitors, who previously had to enter through the inconvenient double doors at the large canopy. Chris Kopytko (standing) works with fellow scouts Joseph and Andre. www.manchesterhistory.org President’s Report by John Dormer [Delivered at the Society’s Annual Meeting on October 23, 2011]
Boeing 737-900ER Interim Special Evaluation Report Dated 14th May 2008 1. Evaluation Team Co-ordinator & Desktop Study Captain Paul Stephens – Flight Operations Training Inspector UK CAA/Chairman JOEB Boeing 737 NG Flyout Team Captain Garth Gray – Regional Manager Operations (Stansted) UK CAA Mrs Janice Fisher – Head of Cabin Safety Inspectorate UK CAA 2. Background This evaluation has been conducted following an enquiry from the Futura as to how the Boeing 737-900ER was being categorised for the UK AOC holder XL Airways. The UK CAA were informed by EASA that Boeing had not made the request for such an evaluation and therefore the aircraft would have to be considered a new type in the interim. The UK CAA in conjunction with EASA requested Boeing to formally request an evaluation of this aircraft. EASA agreed that the UK CAA under the Chairmanship of Captain Paul Stephens (who is in the employ of the UK CAA and the JOEB Chairman for the Boeing 737 NG) conduct an evaluation of this aircraft with the specific objective of establishing whether this could be considered a sub-variant of the Boeing 737-900 or a separate type within the existing licence endorsement. Boeing and XL Airways were requested to send all relevant and applicable paperwork to Captain Stephens so a desktop review could be completed. Captain Stephens with the agreement of UK CAA arranged for a type rated Flight Operations Inspector and the Manager of UK CAA Cabin Safety Inspectorate to fly to Seattle to conduct this evaluation. The results of the desktop evaluation, the observation of the ground technical familiarisation training, aircraft inspection and fly out are detailed below. 14 May 2008 JOEB Interim Report
Boeing B747-400/-400F/-8/-8F Description: Boeing B747-400/-400F/-8/-8F Language: English Final/Draft/Interim: Final OEB Report category: Aeroplanes Manufacturers: BOEING COMPANY (THE) European Aviation Safety Agency: Ottoplatz 1, D-50679 Cologne, Germany - easa.europa.eu An agency of the European Union EUROPEAN AVIATION SAFETY AGENCY Operational Evaluation Board Report Boeing 747-400 / -400F / -8 / -8F Flight Crew Qualifications Report, Rev 2 27 Nov 2013 European Aviation Safety Agency Postfach 10 12 53 D-50452 Köln Germany EASA Operational Evaluation Board Boeing B747-400/-8/-8F – Flight Crew Qualifications Boeing 747-400 / -400F / -8 / -8F Operational Evaluation Board – Flight Crew Qualifications Captain Graham Pass EASA OEB B747 Chairman Captain Klaus Walkner EASA OEB Expert Operational Suitability – Fixed Wing Aircraft – Experts Department, EASA Certification Directorate Captain Herbert Meyer Section Manager, Operational Suitability – Fixed Wing Aircraft – Experts Department, EASA Certification Directorate Revision Record Rev. No. First Issue Content Date new evaluation 18 Oct 2011 Rev 1 B747-8/-8F initial type rating training added. OneEngine Out Ferry Flight Recommendations for B747-400/-400F added. CTLC B747 towards B787 added. 05 Jun 2013 Rev 2 One-Engine Out Ferry Flight Recommendations amended, including B747-8/-8F. 27 Nov 2013 B747-400/-8/-8F OEB, Rev. 2 page 2 EASA Operational Evaluation Board Boeing B747-400/-8/-8F – Flight Crew Qualifications
What is the coverage policy for Anthem Blue Cross members regarding the H1N1 vaccination? Anthem Blue Cross will reimburse for the administration of the H1N1 vaccine for all fully insured members regardless of the individual’s benefit plan and ASO members with self insured employer plans unless the group specifically opts out of covering the vaccine. Additionally, Anthem Blue Cross health plans are waiving deductibles, co-pays and co-insurance for services related to the H1N1 vaccine administration and providing coverage for services regardless of a member’s benefit coverage. How should my practice bill for the H1N1 vaccine and administration service? Please note that effective 9/28/2009, the American Medical Association (AMA) CPT Editorial Panel published a new code specific to administration of the H1N1 vaccine. The newly created CPT code, 90470 should be used to bill the administration of H1N1 immunization. CPT code 90663 is used specifically for the H1N1 vaccine and not for its administration. Since the government is paying for the vaccine, providers do NOT need to bill for this; however, if you choose to use 90663, it should be billed at $0.01 (1 cent) for administrative (non-reimbursable) purposes. The new CPT codes will help to efficiently report and track immunization and counseling services related to the H1N1 vaccine throughout the entire health care system. For administration of both the seasonal flu vaccine and the H1N1 vaccine at the same time, the recommended billing is: 90470 for the H1N1 administration, and for the seasonal flu vaccine administration the appropriate codes from 90466, 90468, 90472 or 90474 based on the individual’s age and CPT coding directions. If the H1N1 vaccine is being administered for two doses and the vaccine administration occurs on different dates of service, please bill each claim using the guidance noted above.
1. PRIOR TO ORDERING VACCINE • Ensure that the vaccine storage unit will continuously maintain temperatures between 35°- 46°F (2°- 8°C). • Document the vaccine storage unit temperature readings twice daily for 5 days prior to placing vaccine in the unit. Temperature logs are available at: http://www.kdheks.gov/immunize/vfc_reporting.htm 2. UPON RECEIPT OF VACCINE, IMMEDIATELY • Unpack the vaccine shipment a) Match the boxes of vaccine with the cold and warm temperature monitors that accompanied the vaccine. This will allow for identification of any vaccine compromised during shipment • Inspect the contents for damage a) Report concerns about the vaccine integrity Call McKesson Customer Service at 877-836-7123. Report the affected Vaccine Type, Vaccine Lot # and Expiration date • Count the vaccine a) Count the doses of vaccine in shipment and compare this amount with the number of doses on the packing slip. If there is a discrepancy with the number of Doses, Lot #, or Expiration Date contact: KDHE Immunization Program 785 296-5592. Be prepared to report the Vaccine Type, Lot No. and Expiration Date of the vaccine package, not the packing slip. • Label all H1NI vaccine a) To easily distinguish H1N1 vaccine from seasonal influenza vaccine. Properly label all containers that hold the H1N1 vaccine and place the vaccine in a refrigerator that will maintain proper storage temperature at all times until vaccine is administered. 3. STORE THE VACCINE AT A CONSTANT TEMPERATURE of 35°- 46°F (2°- 8°C). • Caution: DO NOT FREEZE • Document temperatures twice daily • Refrigerator should be: a) Large enough to hold the largest number of vaccine doses expected at one time b) Used only for storage of biologics